Benzinga | Dec 18, 2020 06:27AM EST

VistaGen Prices 63M Share Common Stock Offering At $0.92/Share

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the "Common Stock"), and 2,000,000 shares of its Series D convertible preferred stock ("Series D Preferred Stock") at a public offering price of $21.16 per share.

Gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be $100 million. All of the securities in the offering are being sold by VistaGen.